Evidence map›Paper›PMID 33243941›Full record

ArticleJournal of biomedical research2020

Characteristics of viral specimens collected from asymptomatic and fatal cases of COVID-19.

Andrew J Gorzalski, Paul Hartley, Chris Laverdure, Heather Kerwin, Richard Tillett, Subhash Verma, Cyprian Rossetto, Sergey Morzunov, Stephanie Van Hooser, Mark W Pandori

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Andrew J GorzalskiNevada State Public Health Laboratory, Reno, NV 89597, USA.
Paul HartleyNevada Genomics Center, Reno, NV 89557, USA.
Chris LaverdureNevada State Public Health Laboratory, Reno, NV 89597, USA.
Heather KerwinWashoe County Health District, Reno, NV 89512, USA.
Richard TillettNevada Institute of Personalized Medicine, University of Nevada Las Vegas, Las Vegas, NV 89154-4022, USA.
Subhash VermaDepartment of Microbiology and Immunology.
Cyprian RossettoDepartment of Microbiology and Immunology.
Sergey MorzunovNevada State Public Health Laboratory, Reno, NV 89597, USA.
Stephanie Van HooserNevada State Public Health Laboratory, Reno, NV 89597, USA.
Mark W PandoriNevada State Public Health Laboratory, Reno, NV 89597, USA.
Nevada Division of Public and Behavioral Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We sought to determine the characteristics of viral specimens associated with fatal cases, asymptomatic cases and non-fatal symptomatic cases of COVID-19. This included the analysis of 1264 specimens found reactive for at least two SARS-CoV-2 specific loci from people screened for infection in Northern Nevada in March-May of 2020. Of these, 30 were specimens from fatal cases, while 23 were from positive, asymptomatic cases. We assessed the relative amounts of SARS-CoV-2 RNA from sample swabs by real-time PCR and use of the threshold crossing value (Ct). Moreover, we compared the amount of human RNase P found on the same swabs. A considerably higher viral load was found to be associated with swabs from cases involving fatality and the difference was found to be strongly statistically significant. Noting this difference, we sought to assess whether any genetic correlation could be found in association with virus from fatal cases using whole genome sequencing. While no common genetic elements were discerned, one branch of epidemiologically linked fatal cases did have two point mutations, which no other of 156 sequenced cases from northern Nevada had. The mutations caused amino acid changes in the 3'-5' exonuclease protein, and the product of the gene,

Indexed as

COVID-19Ct valuereal-time PCRSARS-COV-2viral load

Identifiers

PMID33243941
PMCPMC7718074
OpenAlexW3091130806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.